Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
- 1 July 2025
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500003
Abstract
PURPOSE: There is little guidance for decision making in chronic myeloid leukemia (CML) after patients achieve molecular remission. Our study addresses this gap by developing a risk prediction model for molecular relapse using early longitudinal factors, such as BCR::ABL1 biomarker-level changes and treatment adherence. METHODS: We analyzed electronic health record data of patients with CML diagnosed between 2007 and 2019 from an integrated health system. We used a time-to-event modeling framework using a Cox proportional hazards approach where we evaluated time from molecular remission to molecular relapse. The main predictors were early changes in BCR::ABL1 levels from treatment initiation to the first follow-up measurement (typically around 3 months) and treatment adherence in the first 6 months, categorized as perfect (≥0.98) or less-than-perfect (<0.98). Model performance was assessed through five-fold cross-validation combined with 100 Monte Carlo bootstrapping iterations to ensure robustness and minimize bias. RESULTS: Patients with early improvement in BCR::ABL1 levels had a 70% lower risk relapse (hazard ratio [HR], 0.30 [95% CI, 0.15 to 0.59]) compared with those without early molecular response. Perfect adherence during this critical early phase of treatment was associated with a 56% lower relapse risk (HR, 0.44 [95% CI, 0.22 to 0.85]). Predictive accuracy was high at 6 months (AUC, 0.90; 95% CI, 0.87 to 0.95) and 1-year postremission (AUC, 0.78; 95% CI, 0.74 to 0.81). Relapse risk was significantly higher among Black, Asian, and Hispanic patients compared with non-Hispanic White patients. CONCLUSION: Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.Keywords
This publication has 26 references indexed in Scilit:
- Adherence to BCR-ABL Inhibitors: Issues for CML TherapyClinical Lymphoma Myeloma and Leukemia, 2012
- Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemiaAmerican Journal of Hematology, 2012
- Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational studyAnnals of Hematology, 2011
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on ImatinibJournal of Clinical Oncology, 2010
- Early Adherence to Antiretroviral Medication as a Predictor of Long-Term HIV Virological Suppression: Five-Year Follow Up of an Observational CohortPLOS ONE, 2010
- Early Patterns of Adherence in Adolescents Initiating Highly Active Antiretrovial Therapy Predict Long-Term Adherence, Virologic, and Immunologic ControlAIDS Patient Care and STDs, 2009
- Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer ChemotherapyClinical Cancer Research, 2007
- Treatment Adherence and Long-Term OutcomesCNS Spectrums, 2007
- The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemiaBritish Journal of Haematology, 2003
- Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αLeukemia, 2002